DBV Technologies S. A.
$13.90 +$0.27 (+1.98%) 1D Market openKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 27
Offering paper hit the record (Form S-3).
S-3ASR - DBV Technologies S.A. (0001613780) (Filer)
RECEIPT: SEC FORM S-3, TIMESTAMPED -
Jul 22
From its Feb 10 high, the share price fell 43%.
Peak close $23.80 on Feb 10; trough close $13.63 on Jul 22. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -43% -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Jul 7
The stock moved +11.1% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jul 7 -
Mar 11
The stock moved -12.0% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 11
The story updates itself as events post · The wolf reports; you decide
Snapshot
About DBV Technologies S. A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.